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Background: Integument-related toxicities are common during epidermal growth factor receptor (EGFR)-targeted
therapy. Panitumumab is a fully human monoclonal antibody targeting the EGFR that significantly improves
progression-free survival when added to chemotherapy in patients with metastatic colorectal cancer who have
wild-type (WT) KRAS tumours. Primary efficacy and tolerability results from a phase II single-arm study of first-line
panitumumab plus FOLFIRI in patients with metastatic colorectal cancer have been reported. Here we report
additional descriptive tolerability and quality of life data from this trial.
Methods: Integument-related toxicities and quality of life were analysed; toxicities were graded using modified
National Cancer Institute Common Toxicity Criteria. Kaplan-Meier estimates of time to and duration of first
integument-related toxicity were prepared. Quality of life was measured using EuroQoL EQ-5D and EORTC QLQ-C30.
Best overall response was analysed by skin toxicity grade and baseline quality of life. Change in quality of life was
analysed by skin toxicity severity.
Results: 154 patients were enrolled (WT KRAS n= 86; mutant KRAS n= 59); most (98%) experienced
integument-related toxicities (most commonly rash [42%], dry skin [40%] and acne [36%]). Median time to first
integument-related toxicity was 8 days; median duration was 334 days. Overall, proportionally more patients with
grade 2+ skin toxicity responded (56%) compared with those with grade 0/1 (29%). Mean overall EQ-5D health
state index scores (0.81 vs. 0.78), health rating scores (72.5 vs. 71.0) and QLQ-C30 global health status scores
(65.8 vs. 66.7) were comparable at baseline vs. safety follow-up (8 weeks after completion), respectively and
appeared unaffected by skin toxicity severity.
Conclusions: First-line panitumumab plus FOLFIRI has acceptable tolerability and appears to have little impact on
quality of life, despite the high incidence of integument-related toxicity.
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Many agents are now available for the treatment of meta-
static colorectal cancer, and combining 5-fluorouracil
(5-FU)-based chemotherapy with novel targeted agents is
commonplace. FOLFIRI (folinic acid, infusional 5-FU and
irinotecan) is frequently used in the first- and second-line
settings [1], where it is often given in combination with
the vascular endothelial growth factor A-targeted agent,
bevacizumab [2]. Addition of epidermal growth factor re-
ceptor (EGFR)-targeted agents (e.g. the chimeric antibody
cetuximab or the fully human antibody panitumumab) to
FOLFIRI also significantly improves outcomes in patients
with wild-type (WT) KRAS tumours [3,4]. As median
overall survival (OS) in patients with metastatic colorectal
cancer now approaches 2 years [5], long-term tolerability
of treatment is important.
Although patients have undoubtedly benefitted from the
integration of novel agents, the use of combination regi-
mens inevitably leads to greater treatment-related toxicity
[6] and potentially, adverse effects on quality of life. While
FOLFIRI is associated with severe diarrhoea and neutro-
penia [7], EGFR inhibitors are associated with unique side
effects, mostly different to those seen during chemother-
apy. Because of the key role of EGFR signalling in skin [8],
anti-EGFR therapy frequently results in integument-
related toxicities [9]. Acneiform rash is the most common
but xerosis, paronychia and trichomegaly also occur [10].
Although dermatological toxicities often resolve upon
therapy discontinuation [11], these side effects can nega-
tively affect treatment compliance and quality of life [12].
They can also lead to dose modification or discontinuation
[13], thus potentially affecting the overall effectiveness of
anti-EGFR treatment. Maintenance of quality of life is
therefore an important treatment goal and patient-
reported outcomes (PROs) are a useful way of measuring
the impact of treatment on quality of life.
Study 314 (NCT00508404) was a single-arm, multicen-
tre, phase II study evaluating the efficacy and safety of
panitumumab plus FOLFIRI as first-line treatment for
patients with metastatic colorectal cancer. In this study,
consistently favourable efficacy was observed in patients
with WT vs. mutant (MT) KRAS tumours [14]. Here we
report additional descriptive tolerability and quality of life
data from Study 314.
Methods
Study design and treatments
At the time of study initiation, the value of tumour KRAS
status in patients receiving anti-EGFR therapies was un-
known but after its importance was demonstrated [15,16]
the protocol was amended to evaluate outcomes by KRAS
status (the study was fully enrolled at this time). Panitu-
mumab and FOLFIRI were administered once every
14 days until disease progression, unacceptable toxicity, orconsent withdrawal. If FOLFIRI or panitumumab were
withdrawn/withheld due to toxicity, the other agent could
be continued. On Day 1 of the first cycle, panitumumab
(6 mg/kg) was administered as a 60± 15 min intravenous
(IV) infusion, just prior to chemotherapy; if well tolerated,
subsequent infusions could be administered over
30± 10 min. No panitumumab-specific premedication was
required. FOLFIRI (irinotecan [180 mg/m2] IV over
90± 15 min and leucovorin [400 mg/m2] IV over
120± 15 min [given sequentially/in parallel], followed by a
5-FU 400 mg/m2 bolus and a 5-FU 2400–3000 mg/m2
continuous IV infusion over 46± 2 h) was also adminis-
tered on Day 1 of each cycle. One cycle was defined as the
14-day period following treatment initiation. The study
protocol was approved by the relevant independent ethics
committees and the study was conducted in accordance
with International Conference on Harmonization of Good
Clinical Practice regulations/guidelines.
Patients
Eligible patients were ≥18 years of age, with histologically/
cytologically confirmed, radiologically measurable meta-
static colorectal cancer, and an Eastern Cooperative On-
cology Group (ECOG) performance status of 0–2. All
disease sites must have been evaluated ≤28 days prior to
enrolment and tissue from the primary/metastatic site had
to be available. Patients who had received prior systemic
metastatic colorectal cancer therapy (including anti-EGFR
therapy) were excluded; adjuvant fluoropyrimidine-based
chemotherapy ≥6 months prior to enrolment was permit-
ted. Radiotherapy ≤14 days prior to enrolment was not
allowed and patients must have recovered from all
radiotherapy-related toxicities. Patients with untreated
and symptomatic central nervous system metastases or
significant cardiovascular disease were excluded. All
patients provided signed, informed consent.
KRAS analyses
DNA was extracted from pre-treatment tumour samples
to evaluate the KRAS mutation status and define the pri-
mary analysis population. KRAS testing was performed
centrally at HistoGeneX in Belgium using the DxS kit that
utilises allele-specific, real-time polymerase chain reaction
to detect seven of the most common KRAS mutations.
Integument-related toxicity analyses
The incidence and severity of adverse events (AEs) were
measured continually throughout the study and graded
using National Cancer Institute Common Toxicity Criteria
(NCI CTC v3.0) [17]. Selected skin toxicities (nail changes,
erythema, pruritus, acneiform rash, rash/desquamation, and
ulceration) were graded using a modified version of these
criteria [18]. A safety follow-up visit was scheduled for
8 weeks after treatment completion. To account for any
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patient incidence rates for exposure-adjusted AEs were
analysed. The exposure-adjusted patient incidence was
calculated as the number of patients experiencing the
event divided by the sum of the patient exposure times.
Integument-related toxicities (skin, eye, hair, nail toxicities
and cheilitis) were AEs of particular interest in this study.
The maximum on-study integument-related toxicity was
reported by severity grade. Kaplan-Meier estimates of time
to and duration of first integument-related toxicity were
prepared. Tolerability was assessed overall in the safety
analysis set (all patients who provided informed consent,
were enrolled, and who received ≥1 dose of panitumu-
mab), and the KRAS safety analysis set (as above but
patients also had evaluable KRAS status data [i.e. identical
to the primary analysis set]).
An analysis of best overall response (assessed using
modified Response Evaluation Criteria in Solid Tumours
[19]) by grade of skin toxicity (none/mild [grade 0/1] or
moderate/severe [grade 3/4]) was also performed.
Healthcare resource utilisation
Healthcare resource utilisation during the study, includ-
ing reason for admission and duration of stay in hospital
were reported.
PRO analyses
Quality of life was measured using two validated PRO
tools, the EuroQoL EQ-5D [20] and the EORTC quality of
life Questionnaires (QLQ-C30) [21]. The EuroQoL EQ-5D
is a 5-item scale assessing mobility, self care, usual activ-
ities, pain/discomfort and anxiety/depression to produce a
single value, the EQ-5D health state index score. Health
state index scores range from -0.594 to 1.0 (higher scores
represent better health [1.0 = perfect health]). This ques-
tionnaire also contains a 0 to 100 visual analogue scale
that generates the EQ-5D overall health rating score. The
minimally important differences for the health state index
and overall health rating scores are considered to be 0.08
and 7, respectively [22]. The EORTC QLQ-C30 includes
five functional scales (physical, role, cognitive, emotional
and social), three symptom subscales (fatigue, pain and
nausea/vomiting), a global health status/quality of life
scale, several single items assessing additional symptoms
(dyspnoea, insomnia, appetite loss, constipation and diar-
rhoea) and an item assessing perceived financial impact.
Global health status scores range from 0 to 100 (higher
scores represent better health).
PRO were an exploratory endpoint and so all analyses
are descriptive. PRO analyses were performed on the
KRAS PRO analysis sets; data were summarised overall
and by KRAS mutation status. The KRAS PRO analysis set
comprised enrolled patients who provided informed con-
sent, received ≥1 dose of panitumumab, had evaluableKRAS data, and had baseline and ≥1 post-baseline assess-
ment of EQ-5D or QLQ-C30, as appropriate. The PRO
analysis set also included patients with unevaluable KRAS
status. Mean (standard deviation [SD]) baseline, safety
follow-up and change from baseline to safety follow-up
scores were calculated using actual values. An analysis of
change from baseline EQ-5D health state index score by
best overall response was also performed. The impact of
skin toxicity grade (0/1 or 3/4) on changes from baseline
in health state index, overall health rating and global
health status scores was estimated using a linear mixed
effects model for repeated measures. Least squares means
estimates of average change from baseline within each
group and the difference between the two groups, along
with 95% CIs were calculated in the absence of significant
interaction terms in the model.
Results
Patients and treatment
Overall, 154 patients were enrolled between May 2007
and June 2008; 137 were included in the PRO analysis set
(WT KRAS n=76, MT KRAS n=54, KRAS unevaluable
n=7). Seventeen patients lacking either baseline or post-
baseline PRO assessments were excluded from the PRO
analysis set. Overall, the mean (SD) follow-up time was
37.7 (15.7) weeks (WT vs. MT KRAS: 39.5 weeks vs.
35.8 weeks); eight patients were still receiving at least one
component of treatment at the time of analysis. Most
characteristics were similar between KRAS groups, al-
though the MT KRAS PRO population included propor-
tionally more women (20% vs. 46%), elderly patients
(≥75 years of age; 7% vs. 19%) and patients with colon can-
cer (57% vs. 67%) compared with the WT population
(Table 1). Overall, more men were included in this study
than women (69% vs. 31%).
In the KRAS safety analysis set the mean (SD) cumulative
panitumumab dose (77.0 [43.2] mg/kg vs. 62.2 [34.6] mg/kg)
and number of panitumumab cycles delivered (13.2 [7.5]
vs. 10.9 [6.1]) were higher in the WT vs. the MT KRAS
group. The mean cumulative chemotherapy dose deliv-
ered (any component) was also higher in the WT KRAS
group.
Integument-related toxicity
Nearly all patients (98%) experienced integument-related
toxicities; these comprised skin (97%), eye (38%), hair
(38%) and nail (32%) toxicities, and cheilitis (3%). More
patients in the WT KRAS group had eye toxicities com-
pared with the MT group (45% vs. 29%) whereas more
patients with MT KRAS tumours experienced hair (31%
vs. 51%) and nail (29% vs. 37%) toxicities. Differences in
exposure-adjusted AE rates between the WT and MT
KRAS groups were observed for integument-related toxi-
cities (2938.8 vs. 3284.4 events per 100 patient-years,













Male 61 (80) 29 (54) 95 (69)
Female 15 (20) 25 (46) 42 (31)
Race/ethnicity, n (%)
White/Caucasian 73 (96) 53 (98) 133 (97)
Black/African American 2 (3) 0 (0) 2 (1)
Hispanic/Latino 0 (0) 1 (2) 1 (1)
Japanese 1 (1) 0 (0) 1 (1)
Median age, years (range) 63.5 (21–84) 65.0 (37–80) 64.0 (21–84)
Age group, n (%)
<65 years 40 (53) 26 (48) 71 (52)
≥65 years 36 (47) 28 (52) 66 (48)
<75 years 71 (93) 44 (81) 121 (88)
≥75 years 5 (7) 10 (19) 16 (12)
Primary tumour type, n (%)
Colon cancer 43 (57) 36 (67) 82 (60)
Rectal cancer 33 (43) 18 (33) 55 (40)
Number of metastatic sites, n (%)
1 33 (43) 23 (43) 63 (46)
2 22 (29) 19 (35) 41 (30)
≥3 21 (28) 12 (22) 33 (24)
Location of metastatic sites, n (%)
Liver only 28 (37) 15 (28) 46 (34)
Liver plus other sites 35 (46) 25 (46) 60 (44)
Other sites only 13 (17) 14 (26) 31 (23)
ECOG performance status, n (%)
0 43 (57) 30 (56) 80 (58)
1 30 (39) 20 (37) 50 (36)
2 3 (4) 4 (7) 7 (5)
Mean (SD) PRO scores
EQ-5D health state
index
0.81 (0.22) 0.80 (0.22) 0.81 (0.22)
EQ-5D overall health
rating
71.7 (20.1) 71.9 (19.6) 72.5 (19.8)
QLQ-C30 global health
status
64.4 (22.5) 65.1 (22.8) 65.8 (22.5)
ECOG Eastern Oncology Group; PRO patient-reported outcome.
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icity rates were 68.8 and 106.5 events per 100 patient-
years (WT vs. MT KRAS groups, respectively).
Overall, the most frequently reported integument-
related AEs were rash (42%), dry skin (40%), acne (36%),
alopecia (34%), paronychia (25%), conjunctivitis (21%),and dermatitis acneiform (21%) (Table 2). Rash (43% vs.
26%), dry skin (45% vs. 36%), conjunctivitis (27% vs.
14%), skin fissures (23% vs. 17%), pruritus (24% vs. 14%),
skin toxicity (16% vs. 7%), and erythema (12% vs. 7%)
were more common in the WT KRAS group. Alopecia
(29% vs. 44%) and palmar-plantar erythrodysesthesia
(14% vs. 22%) were more common in the MT group.
Overall, 45% of integument-related toxicities were grade
2 in severity; 36% of patients experienced grade 3 or
higher toxicities. Grade 3 or higher toxicities reported in
>5 patients included rash, acne and paronychia. In gen-
eral, there was no difference between KRAS groups in
the incidence of grade 3 or higher AEs, with the excep-
tion of acne (7% vs. 14%) and palmar-plantar erythrody-
sesthesia syndrome (1% vs. 3%), which were reported
more frequently in the MT KRAS group.
Overall, the median time to first integument-related
toxicity was 8 days (WT vs. MT KRAS group: 8 days vs.
10 days (Table 3)) and the median duration of
integument-related toxicity was 334 days (WT vs. MT
KRAS group: 452 vs. 321 days). Overall, the median time
from last panitumumab dose to resolution of integument-
related toxicity was 71 days (WT vs. MT KRAS group:
103 vs. 71 days).
Response by skin toxicity grade
Of the 152 patients (49%) with measurable disease, 75
(49%) had an objective (complete or partial) response (48/
85 [56%] patients vs. 22/58 [38%] patients in the WT vs.
MT KRAS groups). Overall, objective responses occurred
more commonly in patients with grade 2+ skin toxicity
(56%) than in those with grade 0/1 toxicity (29%) (Table 4).
Similar observations were noted in the WTand MT KRAS
groups.
However, these data may be confounded by the higher
mean panitumumab exposure seen in responding vs. non-
responding patients, overall and in the KRAS WTand MT
groups (Table 5).
Healthcare resource utilisation
Overall, 64% of patients were hospitalised during the
study; the most common reasons for hospitalisation were
chemotherapy (61%), AEs (24%) and normal clinical prac-
tice (9%). The median duration of hospital stay was 3 days.
More patients with WT KRAS status were hospitalised
compared with those with MT KRAS (70% vs. 56%); rea-
sons for hospitalisation were similar between groups and
the median duration of hospital stay was the same.
PRO analyses
EuroQoL EQ-5D health state index and overall health rating
Mean overall EQ-5D health state index and health rating
scores remained stable throughout the study; baseline
Table 2 Most common integument-related toxicities (any grade; incidence ≥10% in the overall group)
n (%)
WT KRAS (n=86) MT KRAS (n=59) Overall (n=154)
Any grade Grade ≥3 Any grade Grade ≥3 Any grade Grade ≥3
Any integument-related AE 84 (98) 29 (34) 58 (98) 22 (37) 151 (98) 55 (36)
Rash 37 (43) 7 (8) 21 (26) 6 (10) 64 (42) 15 (10)
Dry skin 39 (45) 0 (0) 21 (36) 1 (2) 61 (40) 1 (1)
Acne 29 (34) 6 (7) 22 (37) 8 (14) 55 (36) 15 (10)
Alopecia 25 (29) 1 (1) 26 (44) 2 (3) 52 (34) 3 (2)
Paronychia 20 (23) 6 (7) 15 (25) 2 (3) 38 (25) 10 (6)
Conjunctivitis 23 (27) 1 (1) 8 (14) 1 (2) 33 (21) 3 (2)
Dermatitis acneiform 19 (22) 5 (6) 13 (22) 3 (5) 33 (21) 8 (5)
Skin fissures 20 (23) 3 (3) 10 (17) 1 (2) 32 (21) 4 (3)
Pruritus 21 (24) 1 (1) 8 (14) 0 (0) 30 (19) 1 (1)
PPE syndrome 12 (14) 1 (1) 13 (22) 2 (3) 25 (16) 3 (2)
Skin toxicity 14 (16) 4 (5) 4 (7) 1 (2) 18 (12) 5 (3)
Erythema 10 (12) 2 (2) 4 (7) 1 (2) 16 (10) 3 (2)
AE adverse event; PPE palmar-plantar erythrodysaesthesia.
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also similar in the WT and MT KRAS groups (Figure 1).
There appeared to be a trend for better tumour re-
sponse in patients with higher baseline health state index
scores in both the WT and MT KRAS groups. Mean
(SE) baseline scores for responding patients vs. progres-
sing patients with WT KRAS tumours were 0.81 (0.03)Table 3 Kaplan-Meier analysis of integument-related
toxicities
Median (95% CI)
WT KRAS MT KRAS Overall
(n=86) (n=59) (n=154)
Time to first integument toxicity, days [min, max]
Any grade 8.0 (7,0, 10.0) 10.0 (7.0, 13.0) 8.0 (7.0, 11.0)
[0, 155] [0, 125] [0, 155]
Grade ≥3 NE (300.0, NE) NE (175.0, NE) 408.0 (300.0, NE)
[6, 528] [0, 389] [0, 528]
Duration of integument toxicity, days [min, max]
Any grade 452.0 (244.0, NE) 321.0 (228.0, 371.0) 334.0 (244.0, NE)
[14, 492] [19, 445] [14, 492]
Grade ≥3 32.0 (17.0, 43.0) 55.5 (25.0, 80.0) 36.0 (25.0, 54.0)
[5, 322] [5, 268] [5, 322]
Time to resolution, days [min, max]
Any grade 103.0 (55.0, NE) 71.0 (52.0, 86.0) 71.0 (59.0, 162.0)
[0, 309] [5, 162] [0, 309]
Grade ≥3 103.0 (68.0, NE) 86.0 (86.0, 162.0) 86.0 (68.0, 162.0)
[0, 124] [12, 162] [0, 162]
NE not estimable.vs. 0.72 (0.18), respectively; mean scores in responding
vs. progressing patients with MT KRAS tumours were
0.82 (0.05) vs. 0.59 (0.20). Mean (SE) change from base-
line in health state index score in responding patients
with WT KRAS tumours were positive throughout the
study: +0.05 (0.03), +0.07 (0.03), +0.05 (0.03), +0.02
(0.03), +0.05 (0.04) at weeks 8, 16, 24, 32 and safety
follow-up visit, respectively. No consistent trends were
observed in any other subgroup.EuroQoL EQ-5D subscales
Overall, mean mobility, self care, usual activities, pain/
discomfort and anxiety/depression subscale scores
remained stable between baseline and safety follow-up
(Table 6). Results were generally similar between WT
and MT KRAS groups, however, there was high within-
group variability in scores.EORTC QLQ-C30 global health status
Overall, mean global health status scores remained stable
throughout the study; data were similar in the WT and
MT KRAS groups (Figure 1).EORTC QLQ-C30 functioning and symptoms subscales
and single-items
Overall, no clinically meaningful changes in mean func-
tioning and symptoms scores occurred during the study
either overall or by KRAS group (Table 6). Similarly,
mean single-item scores showed little change and results
were similar in each KRAS group (Table 5).
Table 4 Objective response rate by worst skin toxicity grade
Objective response rate, % (95% CI)



















37.5 (15.2, 64.6) 60.9 (48.4, 72.4) 56.5 (45.3, 67.2) 21.0 (6.0, 45.6) 46.2 (30.1, 62.8) 37.9 (25.5, 51.6) 28.6 (14,6, 46.3) 55.6 (46.1, 64.7) 49.3 (41.2, 57.6)
Objective response rate represents the proportion of patients with a best overall response of complete or partial response.
aAll patients in the tumour response analysis set regardless of KRAS evaluability.
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Based on the repeated measures model, the differences
in change from baseline EQ-5D health state index and
overall health rating scores between the two skin toxicity
groups (grade 0/1 or 2+) were not statistically significant
(Table 7). For QLQ-C30 global health status, the model
yielded a significant difference between these two groups
but there were also interactions between baseline global
health status score and skin toxicity overall in the PRO
analysis set and within the MT KRAS PRO population
(data not shown).Discussion
Panitumumab plus FOLFIRI demonstrated acceptable
tolerability in this study, with a profile similar to that
seen for this combination in the second-line setting [4].
The type and incidence of integument-related toxicities
was consistent with that expected for an anti-EGFR anti-
body plus FOLFIRI and was similar to that observed
with cetuximab when administered with irinotecan-
based chemotherapy in this setting [3]. The median dur-
ation of integument-related toxicity and time taken for
resolution of such toxicity was longer in the WT KRAS
group, perhaps reflecting the higher mean cumulative
panitumumab dose and number of panitumumab cycles
delivered in this group compared with the MT group.
Interestingly, the exposure-adjusted AE rates showed
that integument-related toxicities (both overall and
≥ grade 3) were higher in the MT vs. the WT KRAS






Panitumumab cycles delivered – mean
(SD)
16.3 (6.6) 9.2 (6.9)
Cumulative panitumumab dose deliveredb,
mg/kg - mean (SD)
94.2 (37.0) 55.2 (41.5)
Irinotecan cycles delivered mean (SD) 15.6 (6.0) 9.5 (6.3)
Cumulative irinotecan dose deliveredb,
mg/kg - mean (SD)
2635 (1012) 1614 (1026)
Responders comprise those patients with a best overall response of a complete or
response of stable disease, disease progression or those with no post-baseline resp
aAll patients in the tumour response analysis set regardless of KRAS evaluability; bAdgroups should be interpreted within the context of the
relatively small sample size included in this study.
Overall, patients with grade 2+ vs. grade 0/1 skin tox-
icity appeared more likely to respond to treatment, irre-
spective of tumour KRAS status, even though patients
with MT KRAS tumours are not thought to benefit from
panitumumab. However, as noted above, data from this
study are potentially confounded by small patient num-
bers and differences in treatment exposure. For example,
responding patients are likely to undergo a longer dur-
ation of treatment, which in turn is likely to lead to
greater cumulative toxicity. Nonetheless, an association
between severity of skin toxicity and improved outcome
has previously been noted for both cetuximab [23-25]
and panitumumab [26-29] in large phase III trials. The
observation in the present study that patients with MT
KRAS tumours also had better outcomes when they
experienced grade 2+ vs. grade 0/1 skin toxicity, is in
line with other reports suggesting that EGFR-related
skin toxicity may be a prognostic rather than predictive
marker of outcome during therapy [25,27]. For example,
in an analysis of efficacy by skin toxicity grade from the
PRIME study, significantly improved progression-free
survival (PFS) and OS outcomes were observed in those
experiencing higher grades of skin toxicity during pani-
tumumab plus FOLFOX4 treatment, irrespective of
tumour KRAS status [27]. Furthermore, in the recent
German AIO CRC 0104 study, although overall, numeric
differences in objective response rate, PFS and OS were
observed between patients experiencing grade 2–3 vs. 0–
1 skin toxicity during cetuximab plus chemotherapyrs









15.0 (6.4) 8.5 (4.4) 15.8 (6.6) 8.7 (5.7)
83.5 (37.4) 49.8 (26.2) 89.8 (37.5) 51.4 (34.2)
15.7 (4.8) 9.3 (4.5) 15.5 (5.7) 9.4 (5.4)
2603 (754) 1542 (722) 2605 (954) 1569 (869)
partial response; non-responders comprise those patients with a best overall
onse assessment.


























































































Figure 1 Change in EQ-5D a) health state index b) overall
health rating c) QLQ-C30 global health status. Data are
presented as mean (SD) change in score from baseline to safety
follow-up.
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cant when the group of patients with tumours harbouring
codon 12-mutated tumours were examined [25]. In subse-
quent multivariate analyses, male gender and younger age
were significantly correlated with skin toxicity, but no cor-
relation was found with molecular parameters including
KRAS mutation, EGFR status (by fluorescence in situ hy-
bridisation or immunohistochemistry) and EGFR intron-1
polymorphism status [25]. These data suggest that the
reported association between EGFR inhibitor-related skin
toxicity grade and outcome more likely relates to other
factors in the patient impacting on prognosis thanalterations in the EGFR pathway in the tumour, but fur-
ther studies are required to more fully investigate the po-
tential prognostic implications.
EGFR inhibitor-induced rash can have a negative im-
pact on quality of life [30] and proactive management is
recommended [31]. A recent study demonstrated that
pre-emptive treatment is well tolerated and that patients
receiving such treatment during panitumumab therapy
had fewer grade 2+ skin toxicities and less quality of life
impairment than those assigned to reactive treatment
after skin toxicity had developed [32]. Interestingly, not
all studies have reported a negative impact of skin tox-
icity and/or anti-EGFR treatment on quality of life. In a
study comparing panitumumab monotherapy plus best
supportive care with best supportive care alone, more
bothersome skin toxicity according to the modified
dermatology life quality index (mDLQI) was associated
with improved CRC symptoms and quality of life, and
longer PFS and OS in panitumumab-treated patients
[26]. Quality of life was also maintained or deteriorations
lessened for cetuximab plus best supportive care vs. best
supportive care alone in another study [33]. Further
trials have shown either improvements or no deleterious
impact on quality of life when cetuximab was given
alongside irinotecan [34] or FOLFIRI [35] vs. irinotecan/
FOLFIRI alone. Results from the present study are gen-
erally in line with these observations; panitumumab plus
FOLFIRI had minimal impact on quality of life as EQ-
5D and QLQ-C30 scores remained stable throughout
the study, despite the high incidence of integument-
related toxicity. In line with this, in these present ana-
lyses, skin toxicity grade did not appear to significantly
affect the overall change in quality of life during the
study. To our knowledge, this is the first published re-
port in which the impact of skin toxicity grade on qual-
ity or life (EQ-5D health state index and overall health
rating scales) was directly assessed, and therefore adds
to previous reports suggesting that EGFR-targeted mAb
therapy in general or level of skin toxicity bother do not
adversely impact on a patient’s quality of life.
It appears that baseline EQ-5D scores may be prog-
nostic of best tumour response in patients receiving
panitumumab plus FOLFIRI. Overall, however, the PRO
data showed a high degree of within-group variability
due to the relatively small patient numbers in each sub-
group and so any apparent differences should be inter-
preted with caution. Nonetheless, higher baseline quality
of life has previously been associated with improved PFS
and/or OS in patients with advanced gastrointestinal/
colorectal tumours [36,37]. Although to our knowledge,
this is the first report of improved quality of life specific-
ally in patients responding to panitumumab plus FOL-
FIRI treatment, it is perhaps not unexpected as similar
observations have been reported previously in patients
Table 6 PRO EQ-5D and QLQ-C30 subscale scores at baseline and safety follow-up
KRAS PRO analysis set PRO analysis set
WT KRAS (n=76)a MT KRAS (n=54)a Overall (n=137)a
Baseline Safety follow-up Baseline Safety follow-up Baseline Safety follow-up
Mean (SD) EQ-5D subscale scoresb
Mobility 1.13 (0.34) 1.17 (0.38) 1.13 (0.34) 1.12 (0.42) 1.12 (0.33) 1.16 (0.41)
Self care 1.05 (0.23) 1.14 (0.35) 1.13 (0.44) 1.15 (0.51) 1.08 (0.32) 1.15 (0.43)
Usual activities 1.29 (0.56) 1.39 (0.60) 1.35 (0.59) 1.34 (0.65) 1.30 (0.56) 1.38 (0.62)
Pain/discomfort 1.45 (0.58) 1.53 (0.56) 1.53 (0.58) 1.46 (0.56) 1.46 (0.57) 1.51 (0.56)
Anxiety/depression 1.26 (0.50) 1.25 (0.44) 1.39 (0.49) 1.33 (0.48) 1.31 (0.49) 1.30 (0.46)
Mean (SD) QLQ-C30 functioning scoresc
Physical 71.7 (20.1) 71.3 (20.5)d 71.9 (19.6) 78.6 (10.5)d 72.5 (19.8) 74.3 (18.2)d
Role 26.1 (33.4) 30.0 (33.3) 32.1 (35.0) 28.8 (29.8) 27.4 (33.7) 30.3 (31.2)
Cognitive 10.2 (17.7) 13.3 (19.7) 13.6 (22.7) 14.1 (18.2) 11.0 (19.6) 14.4 (19.6)
Emotional 24.3 (23.1) 22.1 (20.0) 26.5 (22.9) 14.9 (19.0) 24.6 (22.6) 19.8 (20.5)
Social 25.8 (33.4) 25.7 (27.8) 23.5 (32.6) 16.7 (21.2) 23.6 (32.5) 22.4 (24.9)
Mean (SD) QLQ-C30 symptom scorese
Fatigue 29.0 (27.8) 31.9 (28.3) 35.4 (31.6) 31.3 (22.6) 31.4 (28.8) 32.3 (26.0)
Pain 19.1 (27.4) 22.9 (27.4) 25.3 (29.6) 19.3 (26.1) 21.2 (27.9) 21.6 (26.6)
Nausea/vomiting 3.3 (10.6) 7.6 (14.2) 8.6 (19.1) 10.6 (19.9) 5.3 (14.6) 8.6 (16.8)
Mean (SD) QLQ-C30 single-item scorese
Dyspnoea 17.1 (27.5) 21.0 (28.1) 23.5 (30.8) 21.2 (21.8) 19.2 (28.5) 21.3 (26.4)
Insomnia 29.8 (35.8) 23.8 (28.7) 28.4 (32.0) 23.2 (27.0) 29.4 (34.2) 25.0 (28.9)
Appetite loss 18.9 (31.0) 15.2 (30.6) 25.9 (35.3) 15.2 (27.8) 20.7 (32.4) 14.4 (28.4)
Constipation 13.3 (23.2) 4.8 (14.3) 14.2 (25.6) 12.1 (23.3) 14.0 (23.8) 9.7 (22.0)
Diarrhoea 20.7 (30.6) 12.4 (23.0) 19.1 (30.8) 22.2 (27.2) 19.5 (30.0) 18.1 (25.6)
Financial impact 8.1 (20.5) 7.6 (18.2) 6.8 (17.6) 11.5 (26.2) 7.2 (18.8) 9.4 (22.0)
aActual ‘n’ number may differ according to subscale item and time point (data from fewer patients were available at safety follow-up vs. baseline); bHigher scores
indicate a better level of functioning of a greater degree of symptomology depending on subscale; cA higher score indicates a better level of functioning/health;
cA higher score indicates a better level of functioning/health; dData not available at safety follow-up, data reported at week 48 instead; eA higher score indicates a
greater degree of symptomology.
Table 7 Change in EQ-5D health state index and EQ-5D overall health rating by severity of skin toxicity
Least-squares adjusteda mean (95% CI)
WT KRAS (n=76)b MT KRAS (n=54)b Overall (n=137)b
EQ-5D health state index
Worst ST grade 0/1 0.03 (-0.10, 0.15) 0.01(-0.12, 0.14) 0.01 (-0.08, 0.09)
Worst ST grade 2+ 0.04 (-0.01, 0.09) -0.02 (-0.11, 0.06) 0.00 (-0.05, 0.04)
Difference -0.01 (-0.14, 0.12) 0.03 (-0.12, 0.19) 0.01 (-0.09, 0.10)
EQ-5D overall health rating
Worst ST grade 0/1 -2.4 (-19.1, 14.4) -3.5 (-12.2, 5.2) -3.4 (-10.9, 4.2)
Worst ST grade 2+ 4.2 (-2.5, 10.9) -6.1 (-12.0,-0.2) -1.8 (-5.9, 2.2)
Difference -6.6 (-24.6, 11.5) 2.6 (-8.0, 13.2) -1.5 (-10.1, 7.1)
Data are presented as least-squares adjusted mean (95% CI) change in score from baseline through disease progression.
aMixed effect model including fixed effects of time, skin toxicity, baseline EQ-5D score, and the interaction between time and skin toxicity (ST). Interaction of ST
with baseline EQ-5D score with P< 0.1 was also included in the final model, as were random effects for intercept and time; bTotal n shown; actual n number varies
for each ST subgroup and scale.
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going treatment with chemotherapy alone [38,39]. These
observations are also in line with the well-documented
association between baseline performance status and OS
in colorectal cancer [40].
Conclusions
First-line panitumumab plus FOLFIRI treatment has an
acceptable tolerability profile, in line with that expected
for such a combination in this setting. Furthermore,
treatment appeared to have little impact on quality of
life, despite the high incidence of integument-related
toxicity. However, the relatively small patient number in
each subgroup gave rise to large variations in scores on
the various PRO scales, and no clear differences
emerged between WT and MT KRAS groups in these
exploratory analyses. These results provide valuable add-
itional insights into the integument-related toxicities
associated with panitumumab, the time taken to develop
such toxicities and their likely duration, as well as add-
ing to the body of evidence evaluating the impact of skin
toxicity severity on treatment efficacy and patient quality
of life. Such insights could help improve patient manage-
ment; by providing healthcare providers with the most
up-to-date information regarding these toxicities they
are able to better inform their patients and reassure
them about the likely lack of impact on their overall
quality of life.
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